Related references
Note: Only part of the references are listed.TFE3-renal carcinoma in an adult patient: A case with strong expression of phosphorylated hepatocyte growth factor (HGFR)/Met
Yuji Sagara et al.
PATHOLOGY RESEARCH AND PRACTICE (2009)
The Hsp90 molecular chaperone: an open and shut case for treatment
Laurence H. Pearl et al.
BIOCHEMICAL JOURNAL (2008)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
The Met tyrosine kinase receptor in development and cancer
Alessandra Gentile et al.
CANCER AND METASTASIS REVIEWS (2008)
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival
Hongkui Jin et al.
CANCER RESEARCH (2008)
c-Met inhibitors with different binding modes - Two is better than one
Isabelle Dussault et al.
CELL CYCLE (2008)
Anti-Angiogenic Targets in the Treatment of Advanced Renal Cell Carcinoma
Daniel Y. C. Heng et al.
CURRENT CANCER DRUG TARGETS (2008)
Grb2 signaling in cell motility and cancer
Alessio Giubellino et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Activation of PI3K is associated with reduced survival in renal cell carcinoma
Axel S. Merseburger et al.
UROLOGIA INTERNATIONALIS (2008)
Kidney cancer: Opportunity for disease specific targeted therapy
W. Marston Linehan
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2008)
C-met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations
Steven F. Bellon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma
Lois J. Malizzia et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts
H. Toni Jun et al.
CLINICAL CANCER RESEARCH (2007)
Xp11 translocation renal cell carcinoma in adults: Expanded clinical, pathologic, and genetic spectrum
Pedram Argani et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
Paul H. Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist
Alessio Giubellino et al.
CANCER RESEARCH (2007)
Targeting the PI3K-Akt pathway in kidney cancer
Jin-Young Park et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma
Hironori Betsunoh et al.
CANCER SCIENCE (2007)
TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition
Masumi Tsuda et al.
CANCER RESEARCH (2007)
Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics
W. Marston Linehan et al.
CLINICAL CANCER RESEARCH (2007)
A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo
Tobias Martens et al.
CLINICAL CANCER RESEARCH (2006)
The !von Hippel-Lindau tumor suppressor gene product represses oncogenic β-catenin signaling in renal carcinoma cells
Benedetta Peruzzi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The ratio of Matriptase/HAI-l mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals
Lotte K. Vogel et al.
BMC CANCER (2006)
Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts
KJ Kim et al.
CLINICAL CANCER RESEARCH (2006)
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
GA Smolen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors
T Burgess et al.
CANCER RESEARCH (2006)
Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers
S Herter et al.
BIOCHEMICAL JOURNAL (2005)
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability
JS Isaacs et al.
CANCER CELL (2005)
Mechanisms and significance of bifunctional NK4 in cancer treatment
K Matsumoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
JG Christensen et al.
CANCER LETTERS (2005)
Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma
MR Morris et al.
CANCER RESEARCH (2005)
Translocation carcinomas of the kidney
P Argani et al.
CLINICS IN LABORATORY MEDICINE (2005)
Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion
Q Xie et al.
ONCOGENE (2005)
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2
D Kirchhofer et al.
FEBS LETTERS (2005)
Conformational lability in serine protease active sites: Structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B
S Shia et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and downregulated in renal cell carcinoma
M Yamauchi et al.
JOURNAL OF UROLOGY (2004)
Morphologic and molecular characterization of renal cell carcinoma in children and young adults
E Bruder et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants
S Berthou et al.
ONCOGENE (2004)
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
P Michieli et al.
CANCER CELL (2004)
The Sema domain of Met is necessary for receptor dimerization and activation
M Kong-Beltran et al.
CANCER CELL (2004)
Hereditary papillary renal carcinoma type I
PG Dharmawardana et al.
CURRENT MOLECULAR MEDICINE (2004)
Early onset hereditary papillary renal carcinoma:: Germline missense mutations in the tyrosine kinase domain of the met proto-oncogene
LS Schmidt et al.
JOURNAL OF UROLOGY (2004)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx
DM Aebersold et al.
ONCOGENE (2003)
Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator Inhibitor-1B (HAI-1B), a new splice variant of HAI-1
D Kirchhofer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Renal development: perspectives on a Wnt-dependent process
AO Perantoni
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2003)
Mutations in the Fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America
JR Toro et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions -: A sensitive and specific immunohistochemical assay
P Argani et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
The von Hippel-Lindau gene, kidney cancer, and oxygen sensing
WG Kaelin
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin
MH Herynk et al.
CLINICAL & EXPERIMENTAL METASTASIS (2003)
Molecular basis of the VHL hereditary cancer syndrome
WG Kaelin
NATURE REVIEWS CANCER (2002)
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome
ML Nickerson et al.
CANCER CELL (2002)
Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1
K Denda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
IPM Tomlinson et al.
NATURE GENETICS (2002)
Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2
LS Schmidt et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: Modeling studies
M Miller et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2001)
Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models
B Cao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases
K Matsumoto et al.
KIDNEY INTERNATIONAL (2001)
Activation of hepatocyte growth factor (HGF) by endogenous HGF activator is required for metanephric kidney morphogenesis in vitro
J van Adelsberg et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Inherited susceptibility to uterine leiomyomas and renal cell cancer
V Launonen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase
SJ Fan et al.
ONCOGENE (2000)
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
MF Di Renzo et al.
ONCOGENE (2000)
Share Paper
